Hitherto Unseen Survival in an ALK-positive-patient with Advanced Stage Adult Ganglioneuroblastoma Treated with Personalized Medicine

Overview

Journal Clin Case Rep

Date 2017 Dec 12

PMID 29225862

Citations 4

Authors

Signe Risum

Ulrich Knigge

Seppo W Langer

Affiliations

Soon will be listed here.

Abstract

Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.

Citing Articles

Adrenal ganglioneuroblastoma with metastasis near the renal hilum in an adult female: A case report and review of the literature.

Zhang X, Zhang Y, Peng D, Shi X, Zhang Z, Wang J Oncol Lett. 2024; 27(4):187.

PMID: 38486945 PMC: 10938287. DOI: 10.3892/ol.2024.14319.

How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas ALK+ Therapy: A Case Report.

Sica A, Sagnelli C, Casale B, Svanera G, Creta M, Calogero A Healthcare (Basel). 2021; 9(2).

PMID: 33572634 PMC: 7912420. DOI: 10.3390/healthcare9020135.

Targeting Inflammation With Nanosized Drug Delivery Platforms in Cardiovascular Diseases: Immune Cell Modulation in Atherosclerosis.

Cervadoro A, Palomba R, Vergaro G, Cecchi R, Menichetti L, Decuzzi P Front Bioeng Biotechnol. 2018; 6:177.

PMID: 30542650 PMC: 6277804. DOI: 10.3389/fbioe.2018.00177.

Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine.

Risum S, Knigge U, Langer S Clin Case Rep. 2017; 5(12):2085-2087.

PMID: 29225862 PMC: 5715430. DOI: 10.1002/ccr3.1262.

References

Garaventa A, Luksch R, Biasotti S, Severi G, Pizzitola M, Viscardi E . A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer. 2003; 98(11):2488-94. DOI: 10.1002/cncr.11797. View

Esiashvili N, Goodman M, Ward K, Marcus Jr R, Johnstone P . Neuroblastoma in adults: Incidence and survival analysis based on SEER data. Pediatr Blood Cancer. 2006; 49(1):41-6. DOI: 10.1002/pbc.20859. View

Risum S, Knigge U, Langer S . Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine. Clin Case Rep. 2017; 5(12):2085-2087. PMC: 5715430. DOI: 10.1002/ccr3.1262. View

Spitz R, Hero B, Simon T, Berthold F . Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res. 2006; 12(11 Pt 1):3368-73. DOI: 10.1158/1078-0432.CCR-05-2495. View

Sorrentino S, Gigliotti A, Sementa A, Morsellino V, Conte M, Erminio G . Neuroblastoma in the adult: the Italian experience with 21 patients. J Pediatr Hematol Oncol. 2014; 36(8):e499-505. DOI: 10.1097/MPH.0000000000000144. View

Rubie H, Chisholm J, Defachelles A, Morland B, Munzer C, Valteau-Couanet D . Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. J Clin Oncol. 2006; 24(33):5259-64. DOI: 10.1200/JCO.2006.06.1572. View

Kwekkeboom D, Krenning E . Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2015; 30(1):179-91. DOI: 10.1016/j.hoc.2015.09.009. View

Bresler S, Weiser D, Huwe P, Park J, Krytska K, Ryles H . ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014; 26(5):682-94. PMC: 4269829. DOI: 10.1016/j.ccell.2014.09.019. View

Masago K, Fujita S, Muraki M, Hata A, Okuda C, Otsuka K . Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations. BMC Cancer. 2015; 15:908. PMC: 4647703. DOI: 10.1186/s12885-015-1925-2. View

10.

Valkema R, Pauwels S, Kvols L, Kwekkeboom D, Jamar F, de Jong M . Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005; 46 Suppl 1:83S-91S. View

11.

Rossler J, Odenthal E, Geoerger B, Gerstenmeyer A, Lagodny J, Niemeyer C . EGFR inhibition using gefitinib is not active in neuroblastoma cell lines. Anticancer Res. 2009; 29(4):1327-33. View

12.

Irwin M, Park J . Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am. 2014; 62(1):225-56. DOI: 10.1016/j.pcl.2014.09.015. View

13.

Bolzacchini E, Martinelli B, Pinotti G . Adult onset of ganglioneuroblastoma of the adrenal gland: case report and review of the literature. Surg Case Rep. 2015; 1:79. PMC: 4567593. DOI: 10.1186/s40792-015-0062-0. View

14.

Jrebi N, Iqbal C, Joliat G, Sebo T, Farley D . Review of our experience with neuroblastoma and ganglioneuroblastoma in adults. World J Surg. 2014; 38(11):2871-4. DOI: 10.1007/s00268-014-2682-0. View

15.

Oberg K . Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs). Theranostics. 2012; 2(5):448-58. PMC: 3360198. DOI: 10.7150/thno.3931. View

16.

Minguet J, Smith K, Bramlage P . Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives. Int J Cancer. 2015; 138(11):2549-61. DOI: 10.1002/ijc.29915. View

17.

Bagatell R, Beck-Popovic M, London W, Zhang Y, Pearson A, Matthay K . Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol. 2008; 27(3):365-70. PMC: 2651034. DOI: 10.1200/JCO.2008.17.9184. View